Strategic Initiatives and Market Expansion Drive Buy Rating for Geron
Tara Bancroft from TD Cowen has maintained a Buy rating on Geron with a price target of $4.00. This rating is supported by strategic initiatives aimed at enhancing market penetration for Rytelo, despite flat sales in Q3. Geron is focusing on increasing awareness among physicians and expanding its reach to earlier-line patients, which could boost revenue. Positive indicators include new ordering accounts and a high re-order rate, although increasing prescription depth remains a priority for sustainable growth.
Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Geron. The associated price target remains the same with $4.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tara Bancroft’s rating is based on several strategic initiatives that Geron is implementing to enhance the market penetration of their product, Rytelo. Despite flat sales in the third quarter, the company is actively working to increase awareness among physicians about Rytelo’s disease-modifying benefits, which is expected to drive greater prescription depth over time.
Furthermore, while the current sales figures reflect a slight decline due to late-line patient discontinuations, Geron is focusing on expanding its reach to earlier-line patients, which could significantly boost revenue. The addition of new ordering accounts and a high re-order rate are positive indicators, but increasing prescription depth among these accounts remains a priority to achieve sustainable growth. These efforts, combined with the potential for long-term impact, underpin Bancroft’s Buy rating on Geron’s stock.
